-
Mapping vascular network architecture in primate brain using ferumoxytol-weighted laminar MRI
24 Jan 2025 16:05 GMT
… ) the intravascular ferumoxytol (Feraheme, ferumoxytol AMAG Pharmaceuticals Inc, Waltham, MA, USA) injection … validating these areal boundaries would benefit from utilizing multimodal approaches.
In …
-
FDA Withdraws Approval Of Makena On Lack Of Favorable Benefit-risk Assessment
10 Apr 2023 06:29 GMT
… reasonably likely to predict clinical benefit. However, the ensuing … did not verify clinical benefit. A sponsor-requested hearing … approval is a favorable benefit-risk assessment; without that … ;
Makena was marketed by AMAG Pharmaceuticals, Inc., which is now …
-
AMAG Pharmaceuticals Files Submission in Response To the Food And Drug Administration’s Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena® (hydroxyprogesterone caproate injection)
14 Dec 2020 13:47 GMT
… 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. has submitted its response … thorough review of the benefits of Makena, particularly among … be useful in clarifying benefit or defining the population … may provide the most benefit. AMAG agrees that additional …
-
AMAG Pharmaceuticals Requests Hearing to Maintain Makena® (Hydroxyprogesterone Caproate Injection) as a Treatment Option for Clinically Indicated Pregnant Patients
14 Oct 2020 20:11 GMT
… patient population who would most benefit from therapy: a retrospective … contains forward-looking information about AMAG Pharmaceuticals, Inc. within the … . AMAG Pharmaceuticals®, the logo and designs, are registered trademarks of AMAG Pharmaceuticals, …
-
AMAG Pharmaceuticals Provides Update on FDA’s Proposal Regarding Makena® (Hydroxyprogesterone Caproate Injection)
06 Oct 2020 01:05 GMT
… a shared-decision on the benefits and risks of the only … Makena supports its continued positive benefit-risk profile, and expectations for … statements. AMAG Pharmaceuticals®, the logo and designs, are registered trademarks of AMAG Pharmaceuticals, Inc …
-
AMAG Pharmaceuticals Provides Update on FDA's Proposal Regarding Makena(R) (Hydroxyprogesterone Caproate Injection)
06 Oct 2020 01:12 GMT
… shared-decision on the benefits and risks of … supports its continued positive benefit-risk profile and … supports its continued positive benefit-risk profile, and …
AMAG Pharmaceuticals, the logo and designs, are registered trademarks of AMAG Pharmaceuticals, …
-
AMAG Pharmaceuticals, Inc. (AMAG) CEO Scott Myers on Q2 2020 Results - Earnings Call Transcript
09 Aug 2020 08:48 GMT
… welcome everyone to the AMAG Pharmaceuticals Second Quarter 2020 Earnings … patient populations that most benefit from 17P. The … way to confirm clinical benefit. Our research indicates … utilized to confirm clinical benefit following the accelerated approval, …
-
AMAG Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Corporate Update
06 Aug 2020 11:00 GMT
… enrollment would demonstrate a benefit of AMAG-423 … team’s adaptability, the benefits of and expectations for … ,012
)
(243,826
)
Income tax benefit
(160
)
(120
)
(60
)
… $
—
$
918
AMAG Pharmaceuticals, Inc.
Reconciliation of Condensed Consolidated …
-
AMAG Pharmaceuticals Completes Divestment of Women’s Health Assets
27 Jul 2020 11:30 GMT
… , among others, expectations about the benefits of the sale of Intrarosa … to successfully achieve the expected benefits of such initiatives in a … statements. AMAG Pharmaceuticals®, the logo and designs, are registered trademarks of AMAG Pharmaceuticals, Inc …
-
AMAG Pharmaceuticals and Norgine B.V. Enter Into Exclusive Licensing Agreement to Commercialize Ciraparantag in Europe, Australia and New Zealand
23 Jul 2020 11:13 GMT
… where providers and patients may benefit from a reversal agent.”
… or otherwise realize the expected benefits of the transaction; uncertainties … statements. AMAG Pharmaceuticals®, the logo and designs, are registered trademarks of AMAG Pharmaceuticals, Inc …
About
© 1995-2025